The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a mTOR inhibitor for the treatment of cancer especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a mTOR inhibitor such as Temsirolimus or Everolimus.

The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a mTOR inhibitor for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a mTOR inhibitor such as Temsirolimus or Everolimus.

Embodiments of the present invention include methods of treating preventing or ameliorating a vascular disease and/or disorder in a diabetic or pre-diabetic patient. The methods include implanting a stent in a vascular region in a diabetic patient and during the implantation procedure delivering a drug formulation from a source other than the stent to the vascular region. The stent may be a bare metal stent or a drug eluting stent such as a metal stent having a coating including a drug. The drug...

592890 Disclosed is the use of a compound of formula (E) and an mTOR inhibitor in the manufacture of a medicament for treating a proliferative disease such as tumors myelomas leukaemia angiogenesis psoriasis restenosis sclerodermitis or fibrosis. An example of an mTOR inhibitor is everolimus and an example of a compound of formula (E) is (R)-2-amino-7-[2-(6-methoxy-pyridin-2-yl)-phenyl]-4-methyl-78-dihydro-6H-pyrido[43-d]pyrimidin-5-one.

The present disclosure discloses processes of Everolimus and intermediates: reacting Sirolimus (Rapamycin) under solvent free conditions with appropriate side chain implying portion wise additions one pot conversion and resin mediated synthesis.

The present disclosure discloses processes of Everolimus and intermediates: reacting Sirolimus (Rapamycin) under solvent free conditions with appropriate side chain implying portion wise additions, one pot conversion, and resin mediated synthesis.

Methods of treating renal cancers and other kidney-related inflammatory disorders with a bioabsorbable polymer scaffold (such as a stent) are described. The treatments are provided as alternative to complete or partial surgical removal of a diseased kidney.